SOPHiA GENETICS SA Ordinary Shares - SOPH STOCK NEWS

SOPHiA GENETICS (NASDAQ: SOPH) announced significant progress in its DEEP-Lung-IV clinical study, with 12 sites across 5 countries participating. The study aims to identify predictive biomarkers for non-small cell lung cancer (NSCLC) immunotherapy responses, addressing the limitations of the current PD-L1 biomarker. The initiative targets enrollment of 4,000 patients, with over 2,000 expected from initial sites. CEO Dr. Jurgi Camblong expressed optimism about the study's momentum and its potential impact in clinical settings.

SOPHiA GENETICS (Nasdaq: SOPH) announced significant leadership changes, hiring Peter Casasanto as Chief BioPharma Officer and Abhimanyu Verma as Chief Technology Officer. This move aligns with their strategy to enhance their footprint in the BioPharma sector. CEO Jurgi Camblong emphasized the importance of innovation in data-driven medicine. Peter brings over 15 years of life sciences experience, while Abhi has over 17 years in technology and data-driven drug development. Their expertise aims to support the company’s goal of advancing healthcare through comprehensive data insights.

SOPHiA GENETICS (Nasdaq: SOPH) has announced that CEO Dr. Jurgi Camblong and CFO Ross Muken will present at the 40^th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 8:15 a.m. ET. The presentation will be accessible live and archived on their website. SOPHiA GENETICS is focused on data-driven medicine and operates the SOPHiA DDM™ Platform used by over 780 institutions worldwide.

SOPHiA GENETICS has launched the DEEP-Lung-IV clinical study (NCT04994795) to analyze multimodal real-world data for predicting immunotherapy responses in 4,000 patients with stage IV non-small cell lung cancer (NSCLC). This large-scale study encompasses approximately 30 sites across North America, Europe, and Latin America. The initiative seeks to identify new predictive biomarkers, enhancing patient stratification and treatment decisions. The company aims to generate actionable insights to improve clinical outcomes in NSCLC patients, leveraging its proprietary SOPHiA DDM™ Platform.

SOPHiA GENETICS (Nasdaq: SOPH) will host a joint symposium with GE Healthcare on December 1, 2021, at the RSNA Annual Meeting in Chicago. The event, focused on advancing data-driven medicine, will explore multimodal digital health data integration using AI-powered analytics. This follows a recent Master Alliance Agreement between the two companies, aiming to enhance collaboration in healthcare solutions, particularly in digital oncology and radiogenomics. The partnership is expected to accelerate the adoption of SOPHiA's platform, enhancing healthcare delivery for cancer patients worldwide.

Balderton Capital has launched its largest-ever fund of $600m to support early-stage startups, complementing its Growth fund raised earlier this year. The firm is now deploying over $1.2bn across Europe, leveraging its extensive investment team of 25 experts. Balderton has made close to 300 investments, including 20 new startups in various sectors. Its portfolio companies have raised over $6bn in follow-on funding this year, highlighting a successful track record with 13 companies reaching unicorn status.

SOPHiA GENETICS (Nasdaq: SOPH) reported a robust 45% year-over-year revenue growth for Q3 2021, reaching $10.4 million. The company executed a Master Alliance Agreement with GE Healthcare to enhance oncology initiatives, expanding its market presence. Total recurring platform customers rose to 375, with a net dollar retention rate of 137%. Despite a net loss of $21.2 million or 35 cents per share, the company anticipates full-year revenue exceeding $40 million, indicating at least 41% growth for 2021.

SOPHiA GENETICS SA (Nasdaq: SOPH) has enhanced its SOPHiA DDM Universal Whole Exome platform with the integration of Agilent's SureSelect Human All Exon v8. This new bioinformatic workflow streamlines analysis from sample to variant report, supporting both germline and cancer applications. Key features include reduced turnaround time, multiple variant detection, tailored analytics for Agilent data, and a comprehensive gene coverage. The solution aims to accelerate research in rare and inherited diseases, making data-driven medicine more accessible.

SOPHiA GENETICS (Nasdaq: SOPH) announced its participation in several upcoming investor conferences, including the Credit Suisse 30th Annual Healthcare Conference on November 11, the Piper Sandler 33rd Annual Healthcare Conference starting November 22, and the Evercore ISI HealthCONx Conference on November 30. Investors can access live and archived presentations through the company's Investors section on their website. SOPHiA GENETICS focuses on data-driven medicine, utilizing its cloud-based SOPHiA DDM™ Platform in over 780 institutions worldwide.